Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL611435 | 0.77 | GRIN2D (0.50) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL631519 | 0.73 | EPHX2 (0.48) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL607672 | 0.70 | GRIN2D (0.46) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL8874180 | 0.64 | GRIN2D (0.48) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3250912 | 0.62 | EPHX2 (0.46) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL812582 | 0.62 | EPHX2 (0.46) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| Ammonia Solution, Strong SCHEMBL11638607 | 0.61 | GRIN2D (0.48) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3188537 | 0.61 | GRIN2D (0.50) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL13754589 | 0.60 | GRIN2D (0.44) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| Pyridine SCHEMBL16244234 | 0.59 | TSHR (0.39) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802675-B2 | Neuroprotective multifunctional compounds and pharmaceutical compositions comprising them | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD (IL) | 2014-08-12 | — | — | US | disclosed |
| US-20120040993-A1 | NEUROPROTECTIVE MULTIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2012-02-16 | — | — | US | disclosed |
| WO-2010086860-A2 | NEUROPROTECTIVE MULTIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040993-A1 | NEUROPROTECTIVE MULTIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | GSR, GRIN1, GRIN2A | EPHX2 1674/4885GRIN2D 9/4885GRIN3B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.